Literature DB >> 28976413

Long-term Patient and Graft Survival of Kidney Transplant Recipients With Hepatitis C Virus Infection in the United States.

Nae-Yun Heo1,2, Ajitha Mannalithara1, Donghee Kim1, Prowpanga Udompap1, Jane C Tan3, W Ray Kim1.   

Abstract

BACKGROUND: Hepatitis C virus (HCV) infection is common among kidney transplant (KTx) recipients. However, the impact of HCV infection on long-term graft and recipient survival after KTx from large-scale data remains to be determined.
METHODS: We used the Organ Procurement and Transplantation Network database to identify all adults undergoing KTx in 2004 to 2006 in the United States. A propensity score was created to match each HCV-positive recipient with an HCV-negative control for unbiased comparisons. Survival analysis was conducted to evaluate recipient and death-censored graft survival.
RESULTS: Out of 33 357 adult primary KTx recipients, 1470 (4.4%) were HCV-positive: 1364 HCV-positive and -negative pairs were selected by propensity score matching. Based on multivariable regression models, HCV is associated with a higher risk of death (hazard ratio [HR], 1.50; 95% confidence interval [95% CI], 1.28-1.75) and graft failure (HR, 1.26; 95% CI, 1.08-1.47). Infection was a more common cause of death in HCV-positive patients than in HCV-negative recipients (HR, 1.64; 95% CI, 1.12-2.42). The incidence of death due to liver failure was 0.23% per year among HCV-positive recipients, whereas no HCV-negative recipients died from liver failure. Graft failure due to recurrent disease was higher in HCV-positive than in HCV-negative recipients (HR, 2.00; 95% CI, 1.06-3.78).
CONCLUSION: HCV infection is associated with decreased long-term recipient and graft survival. Future studies are needed to examine whether recently available, safe, and effective antiviral therapy improves the long-term clinical outcome in these patients.

Entities:  

Mesh:

Year:  2018        PMID: 28976413      PMCID: PMC5820195          DOI: 10.1097/TP.0000000000001953

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  31 in total

1.  Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients.

Authors:  S Baid; M Pascual; W W Williams; N Tolkoff-Rubin; S M Johnson; B Collins; R T Chung; F L Delmonico; A B Cosimi; R B Colvin
Journal:  J Am Soc Nephrol       Date:  1999-01       Impact factor: 10.121

2.  Impact of hepatitis B and C virus on kidney transplantation outcome.

Authors:  P Mathurin; C Mouquet; T Poynard; C Sylla; H Benalia; C Fretz; V Thibault; J F Cadranel; B Bernard; P Opolon; P Coriat; M O Bitker
Journal:  Hepatology       Date:  1999-01       Impact factor: 17.425

3.  Natural history of hepatitis B and C in renal allograft recipients.

Authors:  Adriana Aroldi; Pietro Lampertico; Giuseppe Montagnino; Patrizia Passerini; Margherita Villa; Maria R Campise; Giovanna Lunghi; Antonio Tarantino; Bruno M Cesana; PierGiorgio Messa; Claudio Ponticelli
Journal:  Transplantation       Date:  2005-05-15       Impact factor: 4.939

4.  Impaired kidney transplant survival in patients with antibodies to hepatitis C virus.

Authors:  M A Gentil; J L Rocha; G Rodríguez-Algarra; P Pereira; R López; G Bernal; J Muñoz; M Naranjo; J Mateos
Journal:  Nephrol Dial Transplant       Date:  1999-10       Impact factor: 5.992

5.  Impact of hepatitis B and C on graft loss and mortality of patients after kidney transplantation.

Authors:  Marie K Breitenfeldt; Jens Rasenack; Hans Berthold; Manfred Olschewski; Joachim Schroff; Christoph Strey; Wolfgang H Grotz
Journal:  Clin Transplant       Date:  2002-04       Impact factor: 2.863

6.  Hepatitis C virus-associated membranoproliferative glomerulonephritis in renal allografts.

Authors:  J M Cruzado; S Gil-Vernet; G Ercilla; D Seron; M Carrera; J Bas; J Torras; J Alsina; J M Grinyó
Journal:  J Am Soc Nephrol       Date:  1996-11       Impact factor: 10.121

7.  Long-term outcome in kidney transplant patients with hepatitis C (HCV) infection.

Authors:  S L Orloff; C A Stempel; T L Wright; S J Tomlanovich; W J Amend; P G Stock; J S Melzer; F Vincenti
Journal:  Clin Transplant       Date:  1995-04       Impact factor: 2.863

8.  Hepatitis C--its prevalence in end-stage renal failure patients and clinical course after kidney transplantation.

Authors:  C A Stempel; J Lake; G Kuo; F Vincenti
Journal:  Transplantation       Date:  1993-02       Impact factor: 4.939

9.  Efficacy and Safety of Sofosbuvir-Based Antiviral Therapy to Treat Hepatitis C Virus Infection After Kidney Transplantation.

Authors:  N Kamar; O Marion; L Rostaing; O Cointault; D Ribes; L Lavayssière; L Esposito; A Del Bello; S Métivier; K Barange; J Izopet; L Alric
Journal:  Am J Transplant       Date:  2015-11-20       Impact factor: 8.086

10.  The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation.

Authors:  B J Periera; T L Wright; C H Schmid; A S Levey
Journal:  Transplantation       Date:  1995-10-27       Impact factor: 4.939

View more
  14 in total

1.  Changes in Utilization and Discard of HCV Antibody-Positive Deceased Donor Kidneys in the Era of Direct-Acting Antiviral Therapy.

Authors:  Mary G Bowring; Lauren M Kucirka; Allan B Massie; Tanveen Ishaque; Sunjae Bae; Ashton A Shaffer; Jacqueline Garonzik Wang; Mark Sulkowski; Niraj Desai; Dorry L Segev; Christine M Durand
Journal:  Transplantation       Date:  2018-12       Impact factor: 4.939

2.  Survey of Clinician Opinions on Kidney Transplantation from Hepatitis C Virus Positive Donors: Identifying and Overcoming Barriers.

Authors:  Krista L Lentine; John D Peipert; Tarek Alhamad; Yasar Caliskan; Beatrice P Concepcion; Rachel Forbes; Mark Schnitzler; Su-Hsin Chang; Matthew Cooper; Roy D Bloom; Roslyn B Mannon; David A Axelrod
Journal:  Kidney360       Date:  2020-11-25

3.  Decision-making Among Hepatitis C Virus-negative Transplant Candidates Offered Organs from Donors with HCV Infection.

Authors:  M Elle Saine; Erin M Schnellinger; Michel Liu; Joshua M Diamond; Maria M Crespo; Stacey Prenner; Vishnu Potluri; Christian Bermudez; Heather Mentch; Michaella Moore; Behdad Besharatian; David S Goldberg; Frances K Barg; Peter P Reese
Journal:  Transplant Direct       Date:  2022-07-19

4.  Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN).

Authors:  Roberto Minutolo; Alessio Aghemo; Antonio Chirianni; Fabrizio Fabrizi; Loreto Gesualdo; Edoardo G Giannini; Paolo Maggi; Vincenzo Montinaro; Ernesto Paoletti; Marcello Persico; Francesco Perticone; Salvatore Petta; Massimo Puoti; Giovanni Raimondo; Maria Rendina; Anna Linda Zignego
Journal:  Infection       Date:  2018-09-25       Impact factor: 3.553

5.  Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN).

Authors:  Roberto Minutolo; Alessio Aghemo; Antonio Chirianni; Fabrizio Fabrizi; Loreto Gesualdo; Edoardo G Giannini; Paolo Maggi; Vincenzo Montinaro; Ernesto Paoletti; Marcello Persico; Francesco Perticone; Salvatore Petta; Massimo Puoti; Giovanni Raimondo; Maria Rendina; Anna Linda Zignego
Journal:  J Nephrol       Date:  2018-09-25       Impact factor: 3.902

6.  Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN).

Authors:  Roberto Minutolo; Alessio Aghemo; Antonio Chirianni; Fabrizio Fabrizi; Loreto Gesualdo; Edoardo G Giannini; Paolo Maggi; Vincenzo Montinaro; Ernesto Paoletti; Marcello Persico; Francesco Perticone; Salvatore Petta; Massimo Puoti; Giovanni Raimondo; Maria Rendina; Anna Linda Zignego
Journal:  Intern Emerg Med       Date:  2018-09-25       Impact factor: 3.397

7.  The effect of anemia on the efficacy and safety of treating chronic hepatitis C infection with direct-acting antivirals in patients with chronic kidney disease.

Authors:  Lionel Rostaing; Mohamed Adel Bakr; Ahmed Yahia Elmowafy; Mohamed Hamed Abbas; Ahmed Abdelfattah Denewar; Mohamed Elsayed Mashaly; Gamal Shiha; Salwa Mahmoud El Wasif
Journal:  Int Urol Nephrol       Date:  2020-10-27       Impact factor: 2.370

8.  Hepatitis C Virus Treatment in Patients With Chronic Kidney Disease and in Kidney Transplant Recipients.

Authors:  Melissa Corson; Ashley Moch; Sammy Saab
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-05

9.  Hepatitis C virus infection and global kidney health: the consensus proceedings of the International Federation of Kidney Foundations.

Authors:  Gamal Saadi; Kamyar Kalantar-Zadeh; Piero Almasio; Gloria Ashuntantang; Rashad Barsoum; Annette Bruchfeld; Wahid Doss; Hussein ElFishawy; Maissa El Raziky; Magdy El-Serafy; Fabrizio Fabrizi; Hani Hafez; May Hassaballa; Mona M R Hammady; Hussein Sheishaa; Tarek S Abdelaziz; Ifeoma Ulasi; Elena Zakharova; Michel Jadoul
Journal:  Afr J Nephrol       Date:  2020

10.  Global burden of atherosclerotic cardiovascular disease in people with hepatitis C virus infection: a systematic review, meta-analysis, and modelling study.

Authors:  Kuan Ken Lee; Dominik Stelzle; Rong Bing; Mohamed Anwar; Fiona Strachan; Sophia Bashir; David E Newby; Jasmit S Shah; Michael H Chung; Gerald S Bloomfield; Chris T Longenecker; Shashwatee Bagchi; Shyamasundaran Kottilil; Sarah Blach; Homie Razavi; Peter R Mills; Nicholas L Mills; David A McAllister; Anoop S V Shah
Journal:  Lancet Gastroenterol Hepatol       Date:  2019-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.